Palatin To Seek LeuTech BLA Expedited Review For Appendicitis Detection
This article was originally published in The Gray Sheet
Executive Summary
Palatin Technologies is targeting this summer for submission of a biologics license application for its LeuTech infection imaging agent for detecting appendicitis in patients with equivocal or suspected appendicitis. Phase III trials were completed in March.